vs
艾伯维（ABBV）与通用电气医疗（GEHC）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是通用电气医疗的2.9倍（$16.6B vs $5.7B）。艾伯维净利率更高（10.9% vs 10.3%，领先0.6%）。艾伯维同比增速更快（10.0% vs 7.1%）。过去两年艾伯维的营收复合增速更高（16.2% vs 10.7%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、核磁共振、女性健康筛查、X射线系统）、超声、患者护理解决方案（聚焦远程患者监测、麻醉呼吸护理、心脏病诊断、婴幼儿照护）及制药诊断业务。
ABBV vs GEHC — 直观对比
营收规模更大
ABBV
是对方的2.9倍
$5.7B
营收增速更快
ABBV
高出2.9%
7.1%
净利率更高
ABBV
高出0.6%
10.3%
两年增速更快
ABBV
近两年复合增速
10.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $5.7B |
| 净利润 | $1.8B | $588.0M |
| 毛利率 | 72.6% | 39.7% |
| 营业利润率 | 27.3% | 14.5% |
| 净利率 | 10.9% | 10.3% |
| 营收同比 | 10.0% | 7.1% |
| 净利润同比 | 8354.5% | -18.4% |
| 每股收益（稀释后） | $1.02 | $1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVGEHC
| Q4 25 | $16.6B | $5.7B | ||
| Q3 25 | $15.8B | $5.1B | ||
| Q2 25 | $15.4B | $5.0B | ||
| Q1 25 | $13.3B | $4.8B | ||
| Q4 24 | $15.1B | $5.3B | ||
| Q3 24 | $14.5B | $4.9B | ||
| Q2 24 | $14.5B | $4.8B | ||
| Q1 24 | $12.3B | $4.7B |
净利润ABBVGEHC
| Q4 25 | $1.8B | $588.0M | ||
| Q3 25 | $186.0M | $446.0M | ||
| Q2 25 | $938.0M | $486.0M | ||
| Q1 25 | $1.3B | $564.0M | ||
| Q4 24 | $-22.0M | $721.0M | ||
| Q3 24 | $1.6B | $470.0M | ||
| Q2 24 | $1.4B | $428.0M | ||
| Q1 24 | $1.4B | $374.0M |
毛利率ABBVGEHC
| Q4 25 | 72.6% | 39.7% | ||
| Q3 25 | 66.4% | 38.7% | ||
| Q2 25 | 71.8% | 39.6% | ||
| Q1 25 | 70.0% | 42.1% | ||
| Q4 24 | 70.9% | 42.8% | ||
| Q3 24 | 70.9% | 41.7% | ||
| Q2 24 | 70.9% | 41.4% | ||
| Q1 24 | 66.7% | 40.9% |
营业利润率ABBVGEHC
| Q4 25 | 27.3% | 14.5% | ||
| Q3 25 | 12.1% | 12.7% | ||
| Q2 25 | 31.7% | 13.1% | ||
| Q1 25 | 28.0% | 13.2% | ||
| Q4 24 | -9.9% | 15.1% | ||
| Q3 24 | 26.5% | 13.9% | ||
| Q2 24 | 27.6% | 12.6% | ||
| Q1 24 | 22.7% | 11.6% |
净利率ABBVGEHC
| Q4 25 | 10.9% | 10.3% | ||
| Q3 25 | 1.2% | 8.7% | ||
| Q2 25 | 6.1% | 9.7% | ||
| Q1 25 | 9.6% | 11.8% | ||
| Q4 24 | -0.1% | 13.6% | ||
| Q3 24 | 10.8% | 9.7% | ||
| Q2 24 | 9.5% | 8.8% | ||
| Q1 24 | 11.1% | 8.0% |
每股收益（稀释后）ABBVGEHC
| Q4 25 | $1.02 | $1.28 | ||
| Q3 25 | $0.10 | $0.98 | ||
| Q2 25 | $0.52 | $1.06 | ||
| Q1 25 | $0.72 | $1.23 | ||
| Q4 24 | $-0.03 | $1.58 | ||
| Q3 24 | $0.88 | $1.02 | ||
| Q2 24 | $0.77 | $0.93 | ||
| Q1 24 | $0.77 | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $4.5B |
| 总债务越低越好 | $58.9B | $10.0B |
| 股东权益账面价值 | $-3.3B | $10.4B |
| 总资产 | $134.0B | $36.9B |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资ABBVGEHC
| Q4 25 | $5.3B | $4.5B | ||
| Q3 25 | $5.7B | $4.0B | ||
| Q2 25 | $6.5B | $3.7B | ||
| Q1 25 | $5.2B | $2.5B | ||
| Q4 24 | $5.6B | $2.9B | ||
| Q3 24 | $7.3B | $3.5B | ||
| Q2 24 | $13.2B | $2.0B | ||
| Q1 24 | $18.1B | $2.6B |
总债务ABBVGEHC
| Q4 25 | $58.9B | $10.0B | ||
| Q3 25 | $63.0B | $10.3B | ||
| Q2 25 | $63.0B | $10.3B | ||
| Q1 25 | $64.5B | $8.8B | ||
| Q4 24 | $60.3B | $9.0B | ||
| Q3 24 | $58.5B | $10.3B | ||
| Q2 24 | $58.0B | $9.2B | ||
| Q1 24 | $63.8B | $9.3B |
股东权益ABBVGEHC
| Q4 25 | $-3.3B | $10.4B | ||
| Q3 25 | $-2.6B | $10.0B | ||
| Q2 25 | $-183.0M | $9.7B | ||
| Q1 25 | $1.4B | $9.2B | ||
| Q4 24 | $3.3B | $8.4B | ||
| Q3 24 | $6.0B | $8.3B | ||
| Q2 24 | $6.8B | $7.8B | ||
| Q1 24 | $8.0B | $7.4B |
总资产ABBVGEHC
| Q4 25 | $134.0B | $36.9B | ||
| Q3 25 | $133.9B | $36.1B | ||
| Q2 25 | $137.2B | $35.5B | ||
| Q1 25 | $136.2B | $33.6B | ||
| Q4 24 | $135.2B | $33.1B | ||
| Q3 24 | $143.4B | $33.9B | ||
| Q2 24 | $141.9B | $31.9B | ||
| Q1 24 | $148.9B | $32.2B |
负债/权益比ABBVGEHC
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | 45.44× | 0.95× | ||
| Q4 24 | 18.15× | 1.06× | ||
| Q3 24 | 9.70× | 1.24× | ||
| Q2 24 | 8.56× | 1.18× | ||
| Q1 24 | 7.97× | 1.25× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | — |
| 自由现金流经营现金流 - 资本支出 | $4.9B | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 2.0% | 2.4% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | — |
8季度趋势，按日历期对齐
经营现金流ABBVGEHC
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $5.2B | $94.0M | ||
| Q1 25 | $1.6B | $250.0M | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $2.3B | $-119.0M | ||
| Q1 24 | $4.0B | $419.0M |
自由现金流ABBVGEHC
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | $8.0M | ||
| Q1 25 | $1.4B | $98.0M | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | $-183.0M | ||
| Q1 24 | $3.8B | $274.0M |
自由现金流率ABBVGEHC
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | 0.2% | ||
| Q1 25 | 10.5% | 2.1% | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | -3.8% | ||
| Q1 24 | 31.3% | 5.9% |
资本支出强度ABBVGEHC
| Q4 25 | 2.0% | 2.4% | ||
| Q3 25 | 2.4% | 2.1% | ||
| Q2 25 | 1.7% | 1.7% | ||
| Q1 25 | 1.8% | 3.2% | ||
| Q4 24 | 1.9% | 1.9% | ||
| Q3 24 | 1.7% | 1.9% | ||
| Q2 24 | 1.7% | 1.3% | ||
| Q1 24 | 1.6% | 3.1% |
现金转化率ABBVGEHC
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | 0.19× | ||
| Q1 25 | 1.27× | 0.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | -0.28× | ||
| Q1 24 | 2.95× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
